Karyopharm Therapeutics | KPTI - Ebit


Karyopharm Therapeutics reported $-17.84M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Abbott USD 2.54B 358M Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
J&J USD 6.62B 1.51B Mar/2026
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025
MacroGenics USD -12.1M 32.26M Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.06B 530M Dec/2025
Novartis USD 4.06B 413M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Takeda JPY 257.49B 568.56B Dec/2025
Tectonic Therapeutic USD -21.52M 374K Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025